Madison, Wis.-based Neuropointdx, a division of Stemina Biomarker Discovery, unveiled the Npdx AA test, which identifies metabolic subtypes associated with autism spectrum disorder (ASD). The test, provided through Neuropointdx's CLIA-certified laboratory, may be used to screen children as young as 18 months.